Consistently, studies also demonstrated that mice received adoptive transfer of HPK1 KO T cells became resistant to Lewis lung carcinoma (LLC) tumor growth via mounting effective anti-tumor immune responses [7], suggesting that inhibition of HPK1 could be a viable approach for cancer immune therapy by promoting effector functions of T cells. The gene discussed is MAP4K1; the disease is Carcinoma, Lewis Lung.